Loading
AI
Allakos Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Walker Paul Edward, was filed 23 Sept 2022.
Allakos Inc.: what insiders have been doing
This page follows insider dealings at Allakos Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. No insider at Allakos Inc. has published a filing in the past twelve months. The most recent one dates from 19 May 2025.
Since 2021, the database holds 2 purchases and 7 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
84
Thresholds
n/a
Buy Volume
€5M
2 ops. · all time
Sell Volume
€6M
7 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-US$99.7k
Last declaration on 19 May 2025
Declarations84 total
8,679,726 sharesCommon Stock, $0.001 par valueSEC:0000921895-25-001590:0
2,760,860 sharesCommon StockSEC:0000950170-25-072714:0
512,630 sharesCommon StockSEC:0001104659-25-049427:0
163,426 sharesCommon StockSEC:0001104659-25-049408:0
738,104 sharesCommon StockSEC:0001104659-25-049368:0
14,161 shares@ US$0.260.7% of flowCommon StockSEC:0000950170-25-035648:0
20,017 shares@ US$0.260.1% of flowCommon StockSEC:0000950170-25-035653:0
31,370 shares@ US$0.260.2% of flowCommon StockSEC:0000950170-25-035650:0
21,116 shares@ US$1.100.5% of flowCommon StockSEC:0000950170-24-134678:0
13,138 shares@ US$1.102.9% of flowCommon StockSEC:0000950170-24-134676:0
32,466 shares@ US$1.101.0% of flowCommon StockSEC:0000950170-24-134112:0
10,634 shares@ US$1.1330.0% of flowCommon StockSEC:0000950170-24-134093:0
37,311 shares@ US$0.580.6% of flowCommon StockSEC:0000950170-24-105996:0
45,320 shares@ US$0.6570.0% of flowCommon StockSEC:0000950170-24-105567:0
21,961 shares@ US$0.650.3% of flowCommon StockSEC:0000950170-24-105209:0
13,665 shares@ US$0.651.7% of flowCommon StockSEC:0000950170-24-105208:0
87,064 shares@ US$1.0117.3% of flowCommon StockSEC:0000950170-24-080645:0
37,525 shares@ US$1.141.2% of flowCommon StockSEC:0000950170-24-071398:0
24,749 shares@ US$1.120.6% of flowCommon StockSEC:0000950170-24-071395:0
14,565 shares@ US$1.193.4% of flowCommon StockSEC:0000950170-24-069863:0
32,142 shares@ US$1.358.4% of flowCommon StockSEC:0000950170-24-028122:0
47,392 shares@ US$1.441.4% of flowCommon StockSEC:0000950170-24-027393:0
70,910 shares@ US$1.482.9% of flowCommon StockSEC:0000950170-24-027392:0
6,992 shares@ US$2.506.1% of flowCommon StockSEC:0001209191-23-057521:0
24,753 shares@ US$2.501.7% of flowCommon StockSEC:0001209191-23-057530:0
25 of 84 declarations
About Allakos Inc.
Allakos Inc. is a US-based biotechnology company listed on the Nasdaq (United States) under the ticker ALLK. For French-speaking investors, the name sits in the high-risk, high-optionalité biotech segment: valuation is driven less by current revenues than by clinical data, intellectual-property value, and strategic execution. The company was incorporated in Delaware in March 2012 and has focused on developing antibodies for allergic, inflammatory, and proliferative diseases. Its scientific approach has centered on immunomodulatory receptors found on immune effector cells, with particular emphasis on mast-cell- and siglec-related biology.
Operationally, Allakos has historically been a precommercial R&D organization, funded primarily through equity financing rather than product sales. Over time, its pipeline has included several drug candidates, with AK006 most recently the lead program. In January 2025, the company disclosed that AK006 did not demonstrate therapeutic activity in chronic spontaneous urticaria in a Phase 1 study, and management announced the discontinuation of further development of that candidate. That clinical setback materially changed the company’s profile and triggered a broad strategic review aimed at maximizing shareholder value through alternatives such as a merger, asset sale, licensing transaction, or another strategic deal.
Read moreShow less
From a competitive standpoint, Allakos operates in a crowded and scientifically demanding therapeutic area where large pharmaceutical groups and specialized biotech companies are pursuing similar immunology targets. The company’s potential differentiation has been its focus on mechanisms tied to mast-cell activation and eosinophilic biology, but its investment case has been constrained by the absence of a marketed product and by repeated dependence on clinical proof-of-concept. In 2025, Allakos also implemented a major restructuring, including an approximately 75% workforce reduction, reflecting a capital-preservation strategy while it evaluates strategic alternatives.
Geographically, Allakos is a United States company with operations based in San Carlos, California, and a regulatory correspondence address in Menlo Park, California. It does not currently present itself as a diversified commercial platform with meaningful international sales; instead, it remains an asset-rich but development-stage biotech with a sharply narrowed operating footprint. Recent highlights that matter to investors include the termination of AK006 development, the restructuring program, the active strategic review, and the company’s ongoing reporting as it navigates a post-clinical-failure transition. In short, ALLK is best understood as a Nasdaq-listed biotech in the United States that has moved from pipeline expansion toward balance-sheet and transaction-driven value realization.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
